#BEGIN_DRUGCARD DB01693

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
40925-28-8

# ChEBI_ID:
Not Available

# Chemical_Formula:
C8H13N4O8P

# Chemical_IUPAC_Name:
{[(2S,3R,4R,5R)-5-(3-carbamoyl-1H-1,2,4-triazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Abacavir	Ribavirin Monophosphate may increase the hepatotoxicity of reverse transcriptase inhibitors (nucleoside) such as Abacavir. Lactic acidosis may occur. Consider modifying therapy.

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Ribavirin Monophosphate

# HET_ID:
RVP

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C8H13N4O8P/c9-6(15)7-10-2-12(11-7)8-5(14)4(13)3(20-8)1-19-21(16,17)18/h2-5,8,13-14H,1H2,(H2,9,15)(H2,16,17,18)/t3-,4-,5+,8+/m0/s1

# InChI_Key:
InChIKey=SDWIOXKHTFOULX-PDNLFSCWSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1693

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
324.1846

# Molecular_Weight_Mono:
324.047099924

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1R6A

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.7

# Predicted_LogS:
-2

# Predicted_Water_Solubility:
3.34e+00 g/l

# Primary_Accession_No:
DB01693

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5748447

# PubChem_Substance_ID:
46504726

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02825

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC(=O)C1=NN(C=N1)[C@@H]1O[C@@H](COP(O)(O)=O)[C@H](O)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:24 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
M19197

# Drug_Target_1_GenBank_ID_Protein:
323655

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
>10167 bp
ATGAATGACCAACGGAAAAAGGCGAGAAACACGCCTTTCAATATGCTGAAACGCGAGAGA
AACCGCGTGTCAACTGTACAACAGTTGACAAAGAGATTCTCACTTGGAATGCTGCAGGGA
CGAGGACCACTAAAATTGTTCATGGCCCTGGTGGCATTCCTTCGTTTCCTAACAATCCCA
CCAACAGCAGGGATATTAAAAAGATGGGGAACAATTAAAAAATCAAAGGCTATTAATGTT
CTGAGAGGCTTCAGGAAAGAGATTGGAAGGATGCTGAATATCTTAAACAGGAGACGTAGA
ACTGCAGGCATGATCATCATGCTGATTCCAACAGTGATGGCGTTTCATCTGACCACACGC
AACGGAGAACCACACATGATCGTCAGTAGACAAGAAAAAGGGAAAAGCCTTCTGTTTAAG
ACAAAGGACGGCACGAACATGTGTACCCTCATGGCCATGGACCTTGGTGAGTTGTGTGAA
GACACAATCACGTATAAATGTCCCTTTCTCAAGCAGAACGAACCAGAAGACATAGATTGT
TGGTGCAACTCCACGTCCACATGGGTAACTTATGGGACATGTACCACCACAGGAGAGCAC
AGAAGAGAAAAAAGATCAGTGGCGCTTGTTCCACACGTGGGAATGGGATTGGAGACACGA
ACTGAAACATGGATGTCATCAGAAGGGGCCTGGAAACATGCCCAGAGAATTGAAACTTGG
ATTCTGAGACATCCAGGCTTTACCATAATGGCCGCAATCCTGGCATACACCATAGGAACG
ACGCATTTCCAAAGAGTCCTGATATTCATCCTACTGACAGCCATCGCTCCTTCAATGACA
ATGCGCTGCATAGGAATATCAAATAGGGACTTTGTGGAAGGAGTGTCAGGAGGGAGTTGG
GTTGACATAGTTTTAGAACATGGAAGTTGTGTGACGACGATGGCAAAAAATAAACCAACA
CTGGACTTTGAACTGATAAAAACAGAAGCCAAACAACCCGCCACCTTAAGGAAGTACTGT
ATAGAGGCTAAACTGACCAACACGACAACAGACTCGCGCTGCCCAACACAAGGGGAACCC
ACCCTGAATGAAGAGCAGGACAAAAGGTTTGTCTGCAAACATTCCATGGTAGACAGAGGA
TGGGGAAATGGATGTGGATTATTTGGAAAAGGAGGCATCGTGACCTGTGCCATGTTCACA
TGCAAAAAGAACATGGAGGGAAAAATTGTGCAGCCAGAAAACCTGGAATACACTGTCGTT
ATAACACCTCATTCAGGGGAAGAACATGCAGTCGGAAATGACACAGGAAAACATGGTAAA
GAAGTCAAGATAACACCACAGAGCTCCATCACAGAGGCGGAACTGACAGGCTATGGCACT
GTTACGATGGAGTGCTCTCCAAGAACGGGCCTCGACTTCAATGAGATGGTGTTGCTGCAA
ATGAAAGACAAAGCTTGGCTGGTGCACAGACAATGGTTCCTAGACCTACCGTTGCCATGG
CTGCCCGGAGCAGACACACAAGGATCAAATTGGATACAGAAAGAGACACTGGTCACCTTC
AAAAATCCCCATGCGAAAAAACAGGATGTTGTTGTCTTAGGATCCCAAGAGGGGGCCATG
CATACAGCACTCACAGGGGCTACGGAAATCCAGATGTCATCAGGAAACCTGCTGTTCACA
GGACATCTTAAGTGCAGGCTGAGAATGGACAAATTACAACTTAAAGGGATGTCATACTCC
ATGTGCACAGGAAAGTTTAAAGTTGTGAAGGAAATAGCAGAAACACAACATGGAACAATA
GTCATTAGAGTACAATATGAAGGAGACGGCTCTCCATGCAAGACCCCTTTTGAGATAATG
GATCTGGAAAAAAGACATGTTTTGGGCCGCCTGACCACAGTCAACCCAATTGTAACAGAA
AAGGACAGTCCAGTCAACATAGAAGCAGAACCTCCATTCGGAGACAGCTACATCATCATA
GGAGTGGAACCAGGACAATTGAAGCTGGACTGGTTCAAGAAAGGAAGTTCCATCGGCCAA
ATGTTTGAGACAACAATGAGGGGAGCGAAAAGAATGGCCATTTTGGGCGACACAGCCTGG
GATTTTGGATCTCTGGGAGGAGTGTTCACATCAATAGGAAAGGCTCTCCACCAGGTTTTT
GGAGCAATCTACGGGGCTGCTTTCAGTGGGGTCTCATGGACTATGAAGATCCTCATAGGA
GTTATCATCACATGGATAGGAATGAACTCACGTAGCACATCACTGTCTGTGTCACTGGTA
TTAGTGGGAATCGTGACACTGTACTTGGGAGTTATGGTGCAGGCCGATAGTGGTTGCGTT
GTGAGCTGGAAGAACAAAGAACTAAAATGTGGCAGTGGAATATTCGTCACAGATAACGTG
CATACATGGACAGAACAATACAAGTTCCAACCAGAATCCCCTTCAAAACTGGCTTCAGCC
ATCCAGAAAGCTCATGAAGAGGGCATCTGTGGAATCCGCTCAGTAACAAGACTGGAAAAT
CTTATGTGGAAACAAATAACATCAGAATTGAATCATATTCTATCAGAAAATGAAGTGAAA
CTGACCATCATGACAGGAGACATCAAAGGAATCATGCAGGTAGGAAAACGATCTCTGCGG
CCTCAACCCACTGAGTTGAGGTATTCATGGAAAACATGGGGTAAAGCGAAAATGCTCTCC
ACAGAACTCCATAATCAGACCTTCCTCATTGATGGTCCCGAAACAGCAGAATGCCCCAAC
ACAAACAGAGCTTGGAATTCACTAGAAGTTGAGGACTACGGCTTTGGAGTATTCACTACC
AATATATGGCTAAGATTGAGAGAAAAGCAGGATGCATTTTGTGACTCAAAACTCATGTCA
GCGGCCATAAAGGACAACAGAGCCGTCCATGCTGATATGGGTTATTGGATAGAAAGCGCA
CTCAATGATACATGGAAGATAGAGAAAGCTTCTTTCATTGAAGTCAAAAGTTGCCACTGG
CCAAAGTCACACACTCTATGGAGTAATGGAGTGCTAGAAAGCGAGATGGTAATTCCAAAG
AATTTCGCTGGACCAGTGTCACAACATAATAACAGACCAGGCTATCACACACAAACAGCA
GGACCTTGGCATCTAGGCAAGCTTGAGATGGACTTTGATTTCTGCGAAGGGACTACAGTG
GTGGTAACCGAGGACTGTGGAAACAGAGGGCCCTCTTTAAGAACAACCACTGCCTCAGGA
AAACTCATAACGGAATGGTGTTGTCGATCTTGCACACTACCACCACTAAGATACAGAGGT
GAGGATGGATGCTGGTACGGGATGGAAATCAGACCATTGAAAGAGAAAGAAGAAAATCTG
GTCAGTTCTCTGGTCACAGCCGGACATGGGCAGATTGATAATTTCTCATTAGGAATCTTG
GGAATGGCACTGTTCCTTGAAGAAATGCTCAGGACTCGAGTAGGAACGAAACATGCAATA
TTACTAGTCGCAGTTTCTTTCGTAACGTTAATCACAGGGAACATGTCTTTTAGAGACCTG
GGAAGAGTGATGGTTATGGTGGGTGCCACCATGACAGATGACATAGGCATGGGTGTGACT
TATCTTGCTCTACTAGCAGCTTTCAAAGTCAGACCAACCTTTGCAGCTGGACTGCTCTTG
AGAAAACTGACCTCCAAGGAATTAATGATGACCACCATAGGAATCGTTCTTCTCTCCCAG
AGTAGCATACCAGAGACCATTCTTGAACTGACCGATGCGTTAGCTTTAGGCATGATGGTC
CTCAAGATGGTGAGAAACATGGAAAAATATCAGCTGGCAGTGACCATCATGGCTATTTTG
TGCGTCCCAAATGCTGTGATATTACAGAACGCATGGAAAGTGAGTTGCACAATATTGGCA
GTGGTGTCTGTTTCCCCCCTGTTCTTAACATCCTCACAACAGAAAGCGGACTGGATACCA
TTAGCGTTGACGATCAAAGGCCTCAATCCAACAGCCATTTTTCTAACAACCCTCTCAAGA
ACCAGCAAGAAAAGGAGCTGGCCTTTAAATGAGGCCATCATGGCGGTTGGGATGGTGAGT
ATCTTGGCCAGCTCTCTCTTAAAGAATGACACCCCCATGACAGGACCATTAGTGGCTGGA
GGGCTTCTTACTGTGTGCTACGTACTAACTGGGCGGTCAGCCGATCTGGAACTAGAGAGA
GCTACCGATGTCAAATGGGATGACCAGGCAGAGATATCAGGTAGCAGTCCAATTCTGTCA
ATAACAATATCAGAAGATGGCAGCATGTCAATAAAGAATGAAGAGGAAGAGCAAACATTG
ACTATACTCATTAGAACAGGATTGCTTGTGATCTCAGGACTCTTTCCGGTATCAATACCA
ATTACAGCAGCAGCATGGTACCTGTGGGAAGTAAAGAAACAACGGGCTGGAGTGTTGTGG
GATGTCCCCTCACCACCACCCGTGGGAAAGGCTGAATTGGAAGATGGAGCCTACAGAATC
AAGCAAAAAGGAATCCTTGGATATTCCCAGATCGGAGCTGGAGTTTACAAAGAAGGAACA
TTTCACACAATGTGGCACGTCACACGTGGCGCTGTCCTAATGCATAAGGGGAAGAGGATT
GAACCATCATGGGCGGACGTCAAGAAAGACTTAATATCATATGGAGGAGGTTGGAAGCTA
GAAGGAGAATGGAAAGAAGGAGAAGAAGTCCAGGTCTTGGCATTGGAGCCTGGGAAAAAT
CCAAGAGCCGTCCAAACAAAACCTGGCCTTTTTAGAACCAATACTGGAACCATAGGTGCC
GTATCTCTGGACTTTTCCCCTGGGACGTCAGGATCTCCAATCGTCGACAAAAAAGGAAAA
GTTGTAGGCCTCTATGGCAATGGTGTCGTTACAAGGAGTGGAGCATATGTGAGTGCCATA
GCTCAGACTGAAAAAAGCATTGAAGACAATCCAGAGATTGAAGATGACATCTTTCGAAAG
AGAAGATTGACTATCATGGATCTCCACCCAGGAGCAGGAAAGACAAAGAGATACCTCCCG
GCCATAGTCAGAGAGGCCATAAAAAGAGGCTTGAGAACACTAATCCTAGCCCCCACTAGA
GTCGTGGCAGCTGAAATGGAGGAAGCCCTTAGAGGACTTCCAATAAGATACCAAACTCCA
GCTATCAGGGCTGAGCACACCGGGCGGGAGATTGTGGACTTAATGTGTCATGCCACATTT
ACCATGAGGCTGCTATCACCAATCAGGGTGCCAAATTACAACCTGATCATCATGGACGAA
GCCCATTTTACAGATCCAGCAAGCATAGCAGCTAGGGGATACATCTCAACTCGAGTGGAG
ATGGGTGAGGCAGCTGGAATTTTTATGACAGCCACTCCTCCGGGTAGCAGAGATCCATTT
CCTCAGAGTAATGCACCAATTATGGACGAAGAAAGAGAAATCCCGGAACGTTCATGGAAC
TCCGGGCACGAGTGGGTCACGGATTTTAAAGGAAAGACTGTCTGGTTTGTTCCAAGCATA
AAAACCGGAAATGACATAGCAGCCTGCCTGAGAAAGAATGGAAAGAGGGTGATACAACTC
AGTAGGAAGACCTTTGATTCTGAATATGTCAAGACTAGAACCAATGACTGGGATTTCGTG
GTTACAACTGACATCTCGGAAATGGGTGCCAACTTTAAAGCTGAGAGGGTTATAGACCCC
AGACGCTGCATGAAACCAGTTATACTGACAGACGGCGAAGAGCGGGTGATTCTGGCAGGA
CCCATGCCAGTGACCCACTCTAGTGCAGCACAAAGAAGAGGGAGAATAGGAAGGAATCCA
AGGAATGAAAATGATCAATATATATATATGGGGGAACCCCTGGAAAATGATGAAGACTGT
GCGCACTGGAAGGAAGCTAAGATGCTCCTAGATAACATCAACACACCTGAAGGAATCATT
CCCAGCATGTTCGAGCCAGAGCGTGAAAAGGTGGATGCCATTGACGGTGAATATCGCTTG
AGAGGAGAAGCACGGAAAACTTTTGTGGACCTAATGAGAAGAGGAGACCTACCAGTCTGG
TTGGCTTATAAAGTGGCTGCTGAAGGTATCAACTACGCAGACAGAAGATGGTGTTTTGAC
GGAACCAGAAACAATCAAATCTTGGAAGAAAATGTGGAAGTGGAAATCTGGACAAAGGAA
GGGGAAAGGAAAAAATTGAAACCTAGATGGTTAGATGCTAGGATCTACTCCGACCCACTG
GCGCTAAAAGAATTCGCAGCCGGAAGAAAGTCCCTAACCCTGAACCTAATCACAGAGATG
GGCAGACTCCCAACTTTTATGACTCAGAAGGCCAGAGATGCACTAGACAACTTGGCGGTG
CTGCACACGGCTGAAGCGGGTGGAAAGGCATACAATCATGCTCTCAGTGAACTACCGGAG
ACCCTGGAGACATTGCTTTTGCTGACACTGTTGGCCACAGTCACGGGAGGAATCTTTCTA
TTCCTGATGAGCGGAAGGGGTATAGGGAAGATGACCCTGGGAATGTGCTGCATAATCACG
GCCAGCATCCTCTTATGGTATGCACAAATACAACCACATTGGATAGCAGCTTCAATAATA
TTGGAGTTCTTTCTCATAGTCTTGCTCATTCCAGAACCAGAAAAGCAGAGGACACCCCAG
GATAACCAATTGACTTATGTCATCATAGCCATCCTCACAGTGGTGGCCGCAACCATGGCA
AACGAAATGGGTTTTCTGGAAAAAACAAAGAAAGACCTCGGACTGGGAAACATTGCAACT
CAGCAACCTGAGAGCAACATTCTGGACATAGATCTACGTCCTGCATCAGCATGGACGTTG
TATGCCGTGGCCACAACATTTATCACACCAATGTTGAGACATAGCATTGAAAATTCCTCA
GTAAATGTGTCCCTAACAGCCATAGCTAACCAAGCCACAGTGCTAATGGGTCTCGGGAAA
GGATGGCCATTGTCAAAGATGGACATTGGAGTTCCCCTCCTTGCTATTGGGTGTTACTCA
CAAGTCAACCCTATAACCCTCACAGCGGCTCTTCTTTTATTGGTAGCACATTATGCCATC
ATAGGACCGGGACTTCAAGCCAAAGCAACCAGAGAAGCTCAGAAAAGAGCAGCAGCGGGC
ATCATGAAAAACCCAACTGTGGATGGAATAACAGTGATAGATCTAGATCCAATACCCTAT
GATCCAAAGTTTGAAAAGCAGTTGGGACAAGTAATGCTCCTAGTCCTCTGTGTGACCCAA
GTGCTGATGATGAGGACTACGTGGGCTTTGTGTGAAGCCTTAACTCTAGCAACCGGACCC
GTGTCCACATTGTGGGAAGGAAATCCAGGGAGATTCTGGAACACAACCATTGCAGTGTCA
ATGGCAAACATCTTTAGAGGGAGTTACCTGGCTGGAGCTGGACTTCTCTTTTCTATCATG
AAGAACACAACCAGCACGAGAAGAGGAACTGGCAACATAGGAGAAACGCTAGGAGAGAAA
TGGAAAAGCAGGCTGAACGCATTGGGGAAAAGTGAATTCCAGATCTATAAAAAAAGTGGA
ATTCAAGAAGTGGACAGAACCTTAGCAAAAGAAGGCATTAAAAGAGGAGAAACGGATCAT
CACGCTGTGTCGCGAGGCTCAGCAAAACTGAGATGGTTCGTTGAAAGAAATTTGGTCACA
CCAGAAGGGAAAGTAGTGGACCTTGGTTGCGGCAGAGGGGGCTGGTCATACTATTGTGGA
GGATTAAAGAATGTAAGAGAAGTCAAAGGCTTAACAAAAGGAGGACCAGGACACGAAGAA
CCTATCCCTATGTCAACATATGGGTGGAATCTAGTACGCTTACAGAGCGGAGTTGACGTT
TTTTTTGTTCCACCAGAGAAGTGTGACACATTGTTGTGTGACATAGGGGAATCATCACCA
AATCCCACGGTAGAAGCGGGACGAACACTCAGAGTCCTTAACCTAGTGGAAAATTGGTTG
AACAATAACACCCAATTTTGCGTAAAGGTTCTTAACCCGTACATGCCCTCAGTCATTGAA
AGAATGGAAACCTTACAACGGAAATACGGAGGAGCCTTGGTGAGAAATCCACTCTCACGG
AATTCCACACATGAGATGTACTGGGTGTCCAATGCTTCCGGGAACATAGTGTCATCAGTG
AACATGATTTCAAGAATGCTGATTAACAGATTCACCATGAGACACAAGAAGGCCACCTAT
GAGCCAGATGTCGACCTCGGAAGCGGAACCCGCAATATTGGAATTGAAAGTGAGACACCG
AACCTAGACATAATTGGGAAAAGAATAGAAAAAATAAAACAAGAGCATGAAACGTCATGG
CACTATGACCAAGACCACCCATACAAAACATGGGCTTACCATGGCAGCTATGAAACAAAA
CAGACTGGATCAGCATCATCCATGGTGAACGGAGTAGTCAGATTGCTGACAAAACCCTGG
GACGTTGTTCCAATGGTGACACAGATGGCAATGACAGACACAACTCCTTTCGGACAACAG
CGCGTCTTCAAAGAGAAGGTGGATACGAGAACCCAAGAACCAAAAGAAGGCACAAAAAAA
CTAATGAAAATCACGGCAGAGTGGCTCTGGAAAGAACTAGGAAAGAAAAAGACACCTAGA
ATGTGCACCAGAGAAGAATTCACAAAAAAGGTGAGAAGCAATGCAGCCTTGGGGGCCATA
TTTACCGATGAGAACAAGTGGAAATCGGCGCGTGAGGCTGTTGAAGATAGTAGGTTTTGG
GAGCTGGTTGACAAGGAAAGAAACCTCCATCTTGAAGGGAAATGTGAAACATGTGTATAC
AACATGATGGGAAAAAGAGAGAAAAAACTAGGAGAGTTTGGTAAAGCAAAAGGCAGCAGA
GCCATATGGTACATGTGGCTCGGAGCACGCTTCTTAGAGTTCGAAGCCCTAGGATTTTTG
AATGAAGACCATTGGTTCTCCAGAGAGAACTCCCTGAGTGGAGTAGAAGGAGAAGGGCTG
CATAAGCTAGGTTACATCTTAAGAGAGGTGAGCAAGAAAGAAGGAGGAGCAATGTATGCC
GATGACACCGCAGGCTGGGACACAAGAATCACAATAGAGGATTTAAAAAATGAAGAAATG
ATAACGAACCACATGGCAGGAGAACACAAGAAACTTGCCGAGGCCATTTTTAAATTGACG
TATCAAAACAAGGTGGTGCGTGTGCAAAGACCAACACCAAGAGGCACAGTAATGGACATC
ATATCGAGAAGAGACCAAAGGGGTAGTGGACAAGTTGGTACCTATGGCCTCAACACTTTC
ACCAACATGGAAGCACAACTAATTAGGCAAATGGAGGGGGAAGGAATCTTCAAAAGCATC
CAGCACTTGACAGCCTCAGAAGAAATCGCTGTGCAAGATTGGCTAGCAAGAGTAGGGCGT
GAAAGGTTGTCAAGAATGGCCATCAGTGGAGATGATTGTGTTGTGAAACCTTTAGATGAT
AGATTTGCAAGAGCTCTAACAGCTCTAAATGACATGGGAAAGGTTAGGAAGGACATACAG
CAATGGGAGCCCTCAAGAGGATGGAACGACTGGACACAGGTACCCTTCTGTTCACACCAT
TTTCACGAGTTAATTATGAAAGATGGTCGCACACTCGTAGTTCCATGCAGAAACCAAGAT
GAATTGATCGGCAGAGCCCGAATTTCCCAGGGAGCTGGGTGGTCTTTACGGGAGACGGCC
TGTTTGGGGAAGTCTTACGCCCAAATGTGGAGCTTGATGTACTTCCACAGACGTGATCTC
AGGCTAGCGGCAAATGCCATCTGCTCGGCAGTCCCGTCACACTGGGTTCCAACAAGCCGG
ACAACCTGGTCCATACACGCCAGCCATGAATGGATGACGACGGAAGACATGTTGACAGTT
TGGAACAAAGTGTGGATCCTAGAAAATCCATGGATGGAAGACAAAACTCCAGTGGAATCA
TGGGAGGAAATCCCATACCTGGGAAAAAGAGAAGACCAATGGTGCGGCTCACTGATTGGG
CTGACAAGCAGAGCCACCTGGGCGAAGAATATCCAGACAGCAATAAACCAAGTCAGATCC
CTCATTGGCAATGAGGAATACACAGATTACATGCCATCCATGAAAAGATTCAGAAGAGAA
GAGGAAGAGGCAGGAGTTTTGTGGTAG

# Drug_Target_1_General_Function:
Involved in nucleic acid binding

# Drug_Target_1_General_References:
12032088	Egloff MP, Benarroch D, Selisko B, Romette JL, Canard B: An RNA cap (nucleoside-2'-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. EMBO J. 2002 Jun 3;21(11):2757-68.
12759475	Modis Y, Ogata S, Clements D, Harrison SC: A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):6986-91. Epub 2003 May 20.
12773377	Zhang Y, Corver J, Chipman PR, Zhang W, Pletnev SV, Sedlak D, Baker TS, Strauss JH, Kuhn RJ, Rossmann MG: Structures of immature flavivirus particles. EMBO J. 2003 Jun 2;22(11):2604-13.
2741348	Wright PJ, Cauchi MR, Ng ML: Definition of the carboxy termini of the three glycoproteins specified by dengue virus type 2. Virology. 1989 Jul;171(1):61-7.
2827375	Hahn YS, Galler R, Hunkapiller T, Dalrymple JM, Strauss JH, Strauss EG: Nucleotide sequence of dengue 2 RNA and comparison of the encoded proteins with those of other flaviviruses. Virology. 1988 Jan;162(1):167-80.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2322

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
379224

# Drug_Target_1_Name:
Genome polyprotein

# Drug_Target_1_Number_of_Residues:
3388

# Drug_Target_1_PDB_ID:
1P58

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00869	Flavi_glycoprot
PF00948	Flavi_NS1
PF00949	Peptidase_S7
PF00972	Flavi_NS5
PF01002	Flavi_NS2B
PF01003	Flavi_capsid
PF01004	Flavi_M
PF01005	Flavi_NS2A
PF01349	Flavi_NS4B
PF01350	Flavi_NS4A
PF01570	Flavi_propep
PF01728	FtsJ
PF02832	Flavi_glycop_C
PF07652	Flavi_DEAD

# Drug_Target_1_Protein_Sequence:
>Genome polyprotein [Contains: Capsid protein C
MNDQRKKARNTPFNMLKRERNRVSTVQQLTKRFSLGMLQGRGPLKLFMALVAFLRFLTIP
PTAGILKRWGTIKKSKAINVLRGFRKEIGRMLNILNRRRRTAGMIIMLIPTVMAFHLTTR
NGEPHMIVSRQEKGKSLLFKTKDGTNMCTLMAMDLGELCEDTITYKCPFLKQNEPEDIDC
WCNSTSTWVTYGTCTTTGEHRREKRSVALVPHVGMGLETRTETWMSSEGAWKHAQRIETW
ILRHPGFTIMAAILAYTIGTTHFQRVLIFILLTAIAPSMTMRCIGISNRDFVEGVSGGSW
VDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTDSRCPTQGEP
TLNEEQDKRFVCKHSMVDRGWGNGCGLFGKGGIVTCAMFTCKKNMEGKIVQPENLEYTVV
ITPHSGEEHAVGNDTGKHGKEVKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQ
MKDKAWLVHRQWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVVVLGSQEGAM
HTALTGATEIQMSSGNLLFTGHLKCRLRMDKLQLKGMSYSMCTGKFKVVKEIAETQHGTI
VIRVQYEGDGSPCKTPFEIMDLEKRHVLGRLTTVNPIVTEKDSPVNIEAEPPFGDSYIII
GVEPGQLKLDWFKKGSSIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVF
GAIYGAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVSLVLVGIVTLYLGVMVQADSGCV
VSWKNKELKCGSGIFVTDNVHTWTEQYKFQPESPSKLASAIQKAHEEGICGIRSVTRLEN
LMWKQITSELNHILSENEVKLTIMTGDIKGIMQVGKRSLRPQPTELRYSWKTWGKAKMLS
TELHNQTFLIDGPETAECPNTNRAWNSLEVEDYGFGVFTTNIWLRLREKQDAFCDSKLMS
AAIKDNRAVHADMGYWIESALNDTWKIEKASFIEVKSCHWPKSHTLWSNGVLESEMVIPK
NFAGPVSQHNNRPGYHTQTAGPWHLGKLEMDFDFCEGTTVVVTEDCGNRGPSLRTTTASG
KLITEWCCRSCTLPPLRYRGEDGCWYGMEIRPLKEKEENLVSSLVTAGHGQIDNFSLGIL
GMALFLEEMLRTRVGTKHAILLVAVSFVTLITGNMSFRDLGRVMVMVGATMTDDIGMGVT
YLALLAAFKVRPTFAAGLLLRKLTSKELMMTTIGIVLLSQSSIPETILELTDALALGMMV
LKMVRNMEKYQLAVTIMAILCVPNAVILQNAWKVSCTILAVVSVSPLFLTSSQQKADWIP
LALTIKGLNPTAIFLTTLSRTSKKRSWPLNEAIMAVGMVSILASSLLKNDTPMTGPLVAG
GLLTVCYVLTGRSADLELERATDVKWDDQAEISGSSPILSITISEDGSMSIKNEEEEQTL
TILIRTGLLVISGLFPVSIPITAAAWYLWEVKKQRAGVLWDVPSPPPVGKAELEDGAYRI
KQKGILGYSQIGAGVYKEGTFHTMWHVTRGAVLMHKGKRIEPSWADVKKDLISYGGGWKL
EGEWKEGEEVQVLALEPGKNPRAVQTKPGLFRTNTGTIGAVSLDFSPGTSGSPIVDKKGK
VVGLYGNGVVTRSGAYVSAIAQTEKSIEDNPEIEDDIFRKRRLTIMDLHPGAGKTKRYLP
AIVREAIKRGLRTLILAPTRVVAAEMEEALRGLPIRYQTPAIRAEHTGREIVDLMCHATF
TMRLLSPIRVPNYNLIIMDEAHFTDPASIAARGYISTRVEMGEAAGIFMTATPPGSRDPF
PQSNAPIMDEEREIPERSWNSGHEWVTDFKGKTVWFVPSIKTGNDIAACLRKNGKRVIQL
SRKTFDSEYVKTRTNDWDFVVTTDISEMGANFKAERVIDPRRCMKPVILTDGEERVILAG
PMPVTHSSAAQRRGRIGRNPRNENDQYIYMGEPLENDEDCAHWKEAKMLLDNINTPEGII
PSMFEPEREKVDAIDGEYRLRGEARKTFVDLMRRGDLPVWLAYKVAAEGINYADRRWCFD
GTRNNQILEENVEVEIWTKEGERKKLKPRWLDARIYSDPLALKEFAAGRKSLTLNLITEM
GRLPTFMTQKARDALDNLAVLHTAEAGGKAYNHALSELPETLETLLLLTLLATVTGGIFL
FLMSGRGIGKMTLGMCCIITASILLWYAQIQPHWIAASIILEFFLIVLLIPEPEKQRTPQ
DNQLTYVIIAILTVVAATMANEMGFLEKTKKDLGLGNIATQQPESNILDIDLRPASAWTL
YAVATTFITPMLRHSIENSSVNVSLTAIANQATVLMGLGKGWPLSKMDIGVPLLAIGCYS
QVNPITLTAALLLLVAHYAIIGPGLQAKATREAQKRAAAGIMKNPTVDGITVIDLDPIPY
DPKFEKQLGQVMLLVLCVTQVLMMRTTWALCEALTLATGPVSTLWEGNPGRFWNTTIAVS
MANIFRGSYLAGAGLLFSIMKNTTSTRRGTGNIGETLGEKWKSRLNALGKSEFQIYKKSG
IQEVDRTLAKEGIKRGETDHHAVSRGSAKLRWFVERNLVTPEGKVVDLGCGRGGWSYYCG
GLKNVREVKGLTKGGPGHEEPIPMSTYGWNLVRLQSGVDVFFVPPEKCDTLLCDIGESSP
NPTVEAGRTLRVLNLVENWLNNNTQFCVKVLNPYMPSVIERMETLQRKYGGALVRNPLSR
NSTHEMYWVSNASGNIVSSVNMISRMLINRFTMRHKKATYEPDVDLGSGTRNIGIESETP
NLDIIGKRIEKIKQEHETSWHYDQDHPYKTWAYHGSYETKQTGSASSMVNGVVRLLTKPW
DVVPMVTQMAMTDTTPFGQQRVFKEKVDTRTQEPKEGTKKLMKITAEWLWKELGKKKTPR
MCTREEFTKKVRSNAALGAIFTDENKWKSAREAVEDSRFWELVDKERNLHLEGKCETCVY
NMMGKREKKLGEFGKAKGSRAIWYMWLGARFLEFEALGFLNEDHWFSRENSLSGVEGEGL
HKLGYILREVSKKEGGAMYADDTAGWDTRITIEDLKNEEMITNHMAGEHKKLAEAIFKLT
YQNKVVRVQRPTPRGTVMDIISRRDQRGSGQVGTYGLNTFTNMEAQLIRQMEGEGIFKSI
QHLTASEEIAVQDWLARVGRERLSRMAISGDDCVVKPLDDRFARALTALNDMGKVRKDIQ
QWEPSRGWNDWTQVPFCSHHFHELIMKDGRTLVVPCRNQDELIGRARISQGAGWSLRETA
CLGKSYAQMWSLMYFHRRDLRLAANAICSAVPSHWVPTSRTTWSIHASHEWMTTEDMLTV
WNKVWILENPWMEDKTPVESWEEIPYLGKREDQWCGSLIGLTSRATWAKNIQTAINQVRS
LIGNEEYTDYMPSMKRFRREEEEAGVLW

# Drug_Target_1_Reaction:
nucleoside triphosphate + RNAn = diphosphate + RNAn+1

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
The small proteins NS2A, NS4A and NS4B are hydrophobic, suggesting a possible membrane-related function. NS5 may play a role in the viral RNA replication. The NS2B/NS3 protease complex processes the viral polyprotein

# Drug_Target_1_SwissProt_ID:
P12823

# Drug_Target_1_SwissProt_Name:
POLG_DEN2P

# Drug_Target_1_Synonyms:
Core protein
EC 2.7.7.48
EC 3.4.21.91
Envelope protein M
Flavivirin protease NS2B regulatory subunit
Flavivirin protease NS3 catalytic subunit
Genome polyprotein [Contains: Capsid protein C
Major envelope protein E
Matrix protein
NS1
NS2A
NS4A
NS4B
NS5]
Non- structural protein 1
Non-structural protein 2A
Non-structural protein 4A
Non-structural protein 4B
RNA-directed RNA polymerase

# Drug_Target_1_Theoretical_pI:
8.67

# Drug_Target_1_Transmembrane_Regions:
43-59
101-117
268-284
727-743
757-773

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
IMPDH2

# Drug_Target_2_GenBank_ID_Gene:
J04208

# Drug_Target_2_GenBank_ID_Protein:
307066

# Drug_Target_2_GeneCard_ID:
IMPDH2

# Drug_Target_2_Gene_Name:
IMPDH2

# Drug_Target_2_Gene_Sequence:
>1545 bp
ATGGCCGACTACCTGATTAGTGGGGGCACGTCCTACGTGCCAGACGACGGACTCACAGCA
CAGCAGCTCTTCAACTGCGGAGACGGCCTCACCTACAATGACTTTCTCATTCTCCCTGGG
TACATCGACTTCACTGCAGACCAGGTGGACCTGACTTCTGCTCTGACCAAGAAAATCACT
CTTAAGACCCCACTGGTTTCCTCTCCCATGGACACAGTCACAGAGGCTGGGATGGCCATA
GCAATGGCGCTTACAGGCGGTATTGGCTTCATCCACCACAACTGTACACCTGAATTCCAG
GCCAATGAAGTTCGGAAAGTGAAGAAATATGAACAGGGATTCATCACAGACCCTGTGGTC
CTCAGCCCCAAGGATCGCGTGCGGGATGTTTTTGAGGCCAAGGCCCGGCATGGTTTCTGC
GGTATCCCAATCACAGACACAGGCCGGATGGGGAGCCGCTTGGTGGGCATCATCTCCTCC
AGGGACATTGATTTTCTCAAAGAGGAGGAACATGACTGTTTCTTGGAAGAGATAATGACA
AAGAGGGAAGACTTGGTGGTAGCCCCCCGCAGCATCACACTGAAGGAGGCAAATGAAATT
CTGCAGCGCAGCAAGAAGGGAAAGTTGCCCATTGTAAATGAAGATGATGAGCTTGTGGCC
ATCATTGCCCGGACAGACCTGAAGAAGAATCGGGACTACCCACTAGCCTCCAAAGATGCC
AAGAAACAGCTGCTGTGTGGGGCAGCCATTGGCACTCATGAGGATGACAAGTATAGGCTG
GACTTGCTCGCCCAGGCTGGTGTGGATGTAGTGGTTTTGGACTCTTCCCAGGGAAATTCC
ATCTTCCAGATCAATATGATCAAGTACATCAAAGACAAATACCCTAATCTCCAAGTCATT
GGAGGCAATGTGGTCACTGCTGCCCAGGCCAAGAACCTCATTGATGCAGGTGTGGATGCC
CTGCGGGTGGGCATGGGAAGTGGCTCCATCTGCATTACGCAGGAAGTGCTGGCCTGTGGG
CGGCCCCAAGCAACAGCAGTGTACAAGGTGTCAGAGTATGCACGGCGCTTTGGTGTTCCG
GTCATTGCTGATGGAGGAATCCAAAATGTGGGTCATATTGCGAAAGCCTTGGCCCTTGGG
GCCTCCACAGTCATGATGGGCTCTCTCCTGGCTGCCACCACTGAGGCCCCTGGTGAATAC
TTCTTTTCCGATGGGATCCGGCTAAAGAAATATCGCGGTATGGGTTCTCTCGATGCCATG
GACAAGCACCTCAGCAGCCAGAACAGATATTTCAGTGAAGCTGACAAAATCAAAGTGGCC
CAGGGAGTGTCTGGTGCTGTGCAGGACAAAGGGTCAATCCACAAATTTGTCCCTTACCTG
ATTGCTGGCATCCAACACTCATGCCAGGACATTGGTGCCAAGAGCTTGACCCAAGTCCGA
GCCATGATGTACTCTGGGGAGCTTAAGTTTGAGAAGAGAACGTCCTCAGCCCAGGTGGAA
GGTGGCGTCCATAGCCTCCATTCGTATGAGAAGCGGCTTTTCTGA

# Drug_Target_2_General_Function:
Nucleotide transport and metabolism

# Drug_Target_2_General_References:
10097070	Colby TD, Vanderveen K, Strickler MD, Markham GD, Goldstein BM: Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3531-6.
1969416	Natsumeda Y, Ohno S, Kawasaki H, Konno Y, Weber G, Suzuki K: Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem. 1990 Mar 25;265(9):5292-5.
2902093	Collart FR, Huberman E: Cloning and sequence analysis of the human and Chinese hamster inosine-5'-monophosphate dehydrogenase cDNAs. J Biol Chem. 1988 Oct 25;263(30):15769-72.
7763314	Hager PW, Collart FR, Huberman E, Mitchell BS: Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Biochem Pharmacol. 1995 May 11;49(9):1323-9.
7896827	Zimmermann AG, Spychala J, Mitchell BS: Characterization of the human inosine-5'-monophosphate dehydrogenase type II gene. J Biol Chem. 1995 Mar 24;270(12):6808-14.
7999076	Glesne DA, Huberman E: Cloning and sequence of the human type II IMP dehydrogenase gene. Biochem Biophys Res Commun. 1994 Nov 30;205(1):537-44.
8098009	Glesne D, Collart F, Varkony T, Drabkin H, Huberman E: Chromosomal localization and structure of the human type II IMP dehydrogenase gene (IMPDH2). Genomics. 1993 Apr;16(1):274-7.

# Drug_Target_2_HGNC_ID:
HGNC:6053

# Drug_Target_2_HPRD_ID:
00895

# Drug_Target_2_ID:
796

# Drug_Target_2_Locus:
3p21.2

# Drug_Target_2_Molecular_Weight:
55806

# Drug_Target_2_Name:
Inosine-5'-monophosphate dehydrogenase 2

# Drug_Target_2_Number_of_Residues:
514

# Drug_Target_2_PDB_ID:
1NFB

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00478	IMPDH
PF00571	CBS

# Drug_Target_2_Protein_Sequence:
>Inosine-5'-monophosphate dehydrogenase 2
MADYLISGGTSYVPDDGLTAQQLFNCGDGLTYNDFLILPGYIDFTADQVDLTSALTKKIT
LKTPLVSSPMDTVTEAGMAIAMALTGGIGFIHHNCTPEFQANEVRKVKKYEQGFITDPVV
LSPKDRVRDVFEAKARHGFCGIPITDTGRMGSRLVGIISSRDIDFLKEEEHDCFLEEIMT
KREDLVVAPAGITLKEANEILQRSKKGKLPIVNEDDELVAIIARTDLKKNRDYPLASKDA
KKQLLCGAAIGTHEDDKYRLDLLAQAGVDVVVLDSSQGNSIFQINMIKYIKDKYPNLQVI
GGNVVTAAQAKNLIDAGVDALRVGMGSGSICITQEVLACGRPQATAVYKVSEYARRFGVP
VIADGGIQNVGHIAKALALGASTVMMGSLLAATTEAPGEYFFSDGIRLKKYRGMGSLDAM
DKHLSSQNRYFSEADKIKVAQGVSGAVQDKGSIHKFVPYLIAGIQHSCQDIGAKSLTQVR
AMMYSGELKFEKRTSSAQVEGGVHSLHSYEKRLF

# Drug_Target_2_Reaction:
inosine 5'-phosphate + NAD+ + H2O = xanthosine 5'-phosphate + NADH + H+

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Rate limiting enzyme in the de novo synthesis of guanine nucleotides and therefore is involved in the regulation of cell growth. It may also have a role in the development of malignancy and the growth progression of some tumors

# Drug_Target_2_SwissProt_ID:
P12268

# Drug_Target_2_SwissProt_Name:
IMDH2_HUMAN

# Drug_Target_2_Synonyms:
EC 1.1.1.205
IMP dehydrogenase 2
IMPD 2
IMPDH-II

# Drug_Target_2_Theoretical_pI:
6.90

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB01693
